Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another Rituximab Debuts In India But No Price Contest?

This article was originally published in PharmAsia News

Executive Summary

The privately owned Indian firm Hetero has launched rituximab, its biosimilar version of Roche's MabThera/Rituxan, in India, trailing a clutch of local peers onto the market, although it is not yet clear what price advantages it may have over rivals.

You may also be interested in...



Roche Bolsters India Partnering With Cipla, Entero To Handle Nephrology

Roche is pressing ahead with partnering deals in India as part of efforts to expand access to certain key existing brands and signals intent to continue to explore more collaborations wherever it needs to “reach out to more patients urgently.”

'Affordable' Russian Rituximab Biosimilar On Course In India

Biocad’s biosimilar rituximab appears headed for an Indian debut amid significant competition but the Russian firm appears confident that its “full-cycle production” will give it an edge and also facilitate a flexible pricing policy.

'Affordable' Russian Rituximab Biosimilar On Course In India

Biocad’s biosimilar rituximab appears headed for an Indian debut amid significant competition but the Russian firm appears confident that its “full-cycle production” will give it an edge and also facilitate a flexible pricing policy.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132375

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel